Q1 2022 13F Holders as of 31 Mar 2022
-
Type / Class
-
Equity / *W EXP 08/27/202
-
Total 13F shares
-
635,226
-
Share change
-
-225,710
-
Total reported value
-
$1,226,000
-
Price per share
-
$1.94
-
Number of holders
-
10
-
Value change
-
-$531,795
-
Number of buys
-
1
-
Number of sells
-
8
Institutional Holders of Humacyte, Inc. - *W EXP 08/27/202 (HUMAW) as of Q1 2022
As of 31 Mar 2022,
Humacyte, Inc. - *W EXP 08/27/202 (HUMAW) was held by
10 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
635,226 shares.
The largest 10 holders included
CVI Holdings, LLC, RPO LLC, JANE STREET GROUP, LLC, HRT FINANCIAL LP, Sio Capital Management, LLC, Alpine Global Management, LLC, Exos Asset Management LLC, P SCHOENFELD ASSET MANAGEMENT LP, Diameter Capital Partners LP, and Verition Fund Management LLC.
This page lists
10
institutional shareholders reporting positions in this security
for the Q1 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.